Morgan Stanley downgraded AlloVir to Equal Weight from Overweight with a price target of $1, down from $20, after the company decided to stop further posoleucel development due to futility following a pre-planned DSMB review of multiple ongoing Phase 3 studies. Management plans to analyze the data, but given the disappointing results across all three studies, the firm believes further development is unlikely and given uncertainty related to continued development the firm has removed all revenues from its model.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ALVR: